Welcome to our dedicated page for Ani Pharmaceutic SEC filings (Ticker: ANIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ANI Pharmaceuticals, Inc. filings document financial results, operating updates, governance matters, and material events for its Rare Disease, Generics, and Brands businesses. Form 8-K reports furnish earnings releases, preliminary results, guidance updates, Regulation FD investor presentations, and corporate changes such as independent auditor matters.
ANI proxy filings cover shareholder voting items, board governance, executive compensation, equity awards, and related governance disclosures. The filing record also provides formal context for product and business risks tied to biopharmaceutical development, FDA-regulated generic launches, branded products, commercialization, manufacturing, and capital actions.
ANI Pharmaceuticals senior vice president and chief HR officer Krista Davis reported two stock transactions involving company common shares. On February 26, 2026, she acquired 10,810 shares through a restricted stock award at $77.15 per share, bringing her direct holdings to 60,073 shares. This award is scheduled to vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026. On February 28, 2026, 1,555 shares were withheld at $73.90 per share to cover tax obligations related to the vesting of a prior restricted stock grant, leaving her with 58,518 directly owned shares. The tax withholding is characterized as a payment of tax liability by delivering securities, not an open-market sale.
ANI Pharmaceuticals senior vice president and general counsel Meredith Cook reported equity compensation activity in company stock. On February 26, 2026, Cook acquired 13,895 shares of common stock as a restricted stock award at $77.15 per share, which will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026. On February 28, 2026, 1,555 shares at $73.90 per share were disposed of through shares withheld for tax purposes in connection with the vesting of 3,040 previously granted restricted shares. After these transactions, Cook directly owned 79,890 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported two equity transactions in company common stock. On February 26, 2026, he received a grant of 22,233 restricted shares at $77.15 per share, which will vest in four equal annual installments starting on the first anniversary of that date. On February 28, 2026, 2,773 shares at $73.90 per share were disposed of for tax withholding in connection with the vesting of 6,079 previously granted restricted shares. After these transactions, he directly owned 189,543 common shares.
ANI Pharmaceuticals files its annual report describing a diversified biopharma business built around Rare Disease, Generics, and Brands. The company highlights the September 2024 acquisition of Alimera Sciences, adding the retina drugs ILUVIEN and YUTIQ and expanding its international footprint.
In 2025, the FDA approved an expanded U.S. label for ILUVIEN to treat both diabetic macular edema and chronic non‑infectious uveitis, and cleared a prefilled syringe format for Cortrophin Gel to simplify use. ANI also strengthened its capital structure with a $325.0 million term loan, a $75.0 million revolver, and $316.25 million of convertible notes due 2029, largely used to fund the Alimera deal and refinance prior debt.
The Generics portfolio exceeds 120 products, and management targets 10–15 new launches per year while emphasizing niche, lower‑competition areas. As of June 30, 2025, non‑affiliate equity market value was about $1.3 billion, and as of February 20, 2026, there were 22,414,104 common shares outstanding.
ANI Pharmaceuticals reported record fourth quarter and full-year 2025 results and reaffirmed its 2026 financial guidance. Full-year net revenues reached $883.4 million, up 43.8%, with Q4 revenues of $247.1 million, up 29.6% from 2024.
Rare Disease revenue grew strongly to $422.6 million in 2025, led by Cortrophin Gel at $347.8 million, up 75.6%. GAAP net income available to common shareholders was $77.2 million versus a prior-year loss, and adjusted non-GAAP EBITDA rose to $229.8 million, up 47.3%. 2026 guidance calls for total revenue of $1.055–$1.115 billion and adjusted diluted EPS of $8.83–$9.34. The company ended 2025 with $285.6 million in cash and $629.1 million in principal debt.
ANI Pharmaceuticals executive Christopher Mutz reported an open-market sale of company stock. On the reported date, he sold 5,323 shares of ANI Pharmaceuticals common stock at a weighted average price of $78.02 per share, with individual trade prices ranging from $77.20 to $78.58.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025. After this sale, Mutz directly holds 84,840 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals senior vice president and chief human resources officer Krista Davis sold a total of 3,814 shares of Common Stock in open‑market transactions. She sold 2,084 shares at a weighted average price of $77.53 on February 19, 2026 and 1,730 shares at $77.99 on February 20, 2026. The sales were executed under a Rule 10b5‑1 trading plan adopted on September 18, 2025, and she held 49,263 shares directly after the most recent sale.
Rowland Thomas Andrew reported disposition transactions in a Form 4 filing for ANIP. The filing lists transactions totaling 1,051 shares at a weighted average price of $77.00 per share. Following the reported transactions, holdings were 38,109 shares.
ANI Pharmaceuticals executive Christopher Mutz, Head of Rare Disease, reported share transactions in company common stock. On February 12, he completed an open-market sale of 7,032 shares at a weighted average price of $76.55 under a Rule 10b5-1 trading plan adopted on June 16, 2025. That same day, 3,173 shares and, on February 14, 2,403 shares were withheld to cover tax liabilities tied to vesting of previously granted restricted stock awards, at prices of $76.70 and $77.36, respectively. Following these transactions, Mutz directly held 90,163 ANI Pharmaceuticals shares.
Lalwani Nikhil reported disposition transactions in a Form 4 filing for ANIP. The filing lists transactions totaling 21,986 shares at a weighted average price of $77.01 per share. Following the reported transactions, holdings were 358,574 shares.